In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors
Stuart Lutimba, Baraya Saleem, Eiman Aleem, Mohammed A. Mansour · 2024
Read In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors by Stuart Lutimba, Baraya Saleem, Eiman Aleem, Mohammed A. Mansour (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676455.txt.
Description
Stuart Lutimba and co-authors screen approved drugs in silico for a double hit on two cancer receptors in a 2024 study. The receptors VEGFR-2 and c-Met each drive tumor growth and blood vessel supply, and blocking one alone invites resistance. A single drug blocking both could outflank that escape.
Computer docking and molecular dynamics simulations tested 2,016 approved drugs against both targets. Two drugs proved strong but single-minded, one for each receptor. A third, the diuretic triamterene, bound both receptors specifically and strongly. Simulations mapped the exact residues it grips in each active site. The authors present triamterene as a repurposing candidate and the screen as a template for dual-inhibitor hunts, pending lab validation.
Catalog record
| CREATOR | Stuart Lutimba, Baraya Saleem, Eiman Aleem, Mohammed A. Mansour |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |